1. Bergren, M. S., Chao, R. S., Meulman, P. A., Sarver, R. W., Lyster, M A., Havens, J. L., and Hawley, M., 1996, Solid phases of delavirdine mesylate, J. Pharm. Sci. 85:834–841.
2. Chang, M., Sood, V. K., Kloosterman, D. A., Hauer, M. J., Gaerness, P. E., Sanders, P. E., and Vrbanac, J. J., 1997, Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys, Drug Metab. Dispos. 25:828–839.
3. Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., and Fagerness, P. E., 1997, Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdin in rats, Drug Metab. Dispos. 25:228–242.
4. Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Zhang, W., and Granstetter, D. G., 1997, Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice, Drug Metab. Dispos. 25:814–827.
5. Chong, K. T., Pagano, P. J., and Hinshaw, R. R., 1994, Bisheteroaryl piperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3-dideoxycytidine synergistically inhibits human immunodeficiency virus type I replication in vitro, Antimicrob. Agents Chemother. 38:288–293.